Jenny C. Chang, MD

Emily Herrmann Chair in Cancer Research & Director, Cancer Center
Professor of Cancer, Institute for Academic Medicine
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College


Dr. Jenny C. Chang is the Director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research in Houston, Texas. She obtained her medical degree at Cambridge University in England, and then completed fellowship training in medical oncology at the Royal Marsden Hospital/Institute for Cancer Research in the United Kingdom. She was also awarded a research doctorate from the University of London. Her recent work has focused on the intrinsic therapy resistance of cancer stem cells, which has led to several publications and international presentations. Dr. Chang’s clinical research aims to evaluate novel biologic agents in breast cancer patients.

Description of Research

Dr. Chang has worked in the field of tumor-initiating cells for more than ten years. After her discovery that tumor-initiating cells are chemo-resistant, and that targeting the EGFR/HER2 pathway can decrease this subpopulation, Dr. Chang has played a key role in demonstrating some of the limitations and mechanisms of tumor-initiating cells (Creighton et al., 2009; Li et al., 2008). Her work is now focused on the mechanisms that regulate TICs, as well as initiating and planning clinical trials that target this critical tumor initiating subpopulation. She is also interested in characterizing the cross-talk between these different pathways that may lead to mechanisms of resistance, and has identified some of the chief regulatory pathways involved in TIC self-renewal. She is a world-renown clinical investigator, credited as one of the first to describe intrinsic chemo-resistance of tumor-initiating cells.

Areas Of Expertise

Cancer Stem cells Breast cancer High throughput
Education & Training

MD , University of Cambridge
Research Doctorate , University of London

Molecular characterization of breast cancer CTCs associated with brain metastasis
Boral, D, Vishnoi, M, Liu, HN, Yin, W, Sprouse, ML, Scamardo, A, Hong, DS, Tan, TZ, Thiery, JP, Chang, JC & Marchetti, D 2017, Nature Communications, vol 8, no. 1, 196. DOI: 10.1038/s41467-017-00196-1

A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): Responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status, and Ki67
Jovanovic, B, Mayer, IA, Mayer, EL, Abramson, VG, Bardia, A, Sanders, ME, Kuba, MG, Estrada, MV, Beeler, JS, Shaver, TM, Johnson, KC, Sanchez, V, Rosenbluth, JM, Dillon, PM, Forero-Torres, A, Chang, JC, Meszoely, IM, Grau, AM, Lehmann, BD, Shyr, Y, Sheng, Q, Chen, SC, Arteaga, CL & Pietenpol, JA 2017, Clinical Cancer Research, vol 23, no. 15, pp. 4035-4045. DOI: 10.1158/1078-0432.CCR-16-3055

Role of RPL39 in Metaplastic Breast Cancer
Dave, B, Gonzalez, DD, Liu, ZB, Li, X, Wong, H, Granados, S, Ezzedine, NE, Sieglaff, DH, Ensor, JE, Miller, KD, Radovich, M, KarinaEtrovic, A, Gross, SS, Elemento, O, Mills, GB, Gilcrease, MZ & Chang, JC 2017, Journal of the National Cancer Institute, vol 109, no. 6. DOI: 10.1093/jnci/djw292

Deep learning analytics for diagnostic support of breast cancer disease management
He, T, Puppala, M, Ogunti, R, Mancuso, JJ, Yu, X, Chen, S, Chang, JC, Patel, TA & Wong, STC 2017, . in 2017 IEEE EMBS International Conference on Biomedical and Health Informatics, BHI 2017., 7897281, IEEE, pp. 365-368, 4th IEEE EMBS International Conference on Biomedical and Health Informatics, BHI 2017, Orlando, United States, 16-19 February. DOI: 10.1109/BHI.2017.7897281

Treatment Outcomes and Prognostic Factors in Male Patients With Stage IV Breast Cancer: A Population-based Study
Chen, W, Huang, Y, Lewis, GD, Szeja, SS, Hatch, SS, Farach, A, Miltenburg, D, Butler, EB, Chang, JC & Teh, BS 2017, Clinical Breast Cancer. DOI: 10.1016/j.clbc.2017.07.005

Bromodomain and extraterminal protein inhibition blocks growth of triple-negative breast cancers through the suppression of Aurora kinases
Sahni, JM, Gayle, SS, Bonk, KLW, Vite, LC, Yori, JL, Webb, B, Ramos, EK, Seachrist, DD, Landis, MD, Chang, JC, Bradner, JE & Keri, RA 2016, Journal of Biological Chemistry, vol 291, no. 45, pp. 23756-23768. DOI: 10.1074/jbc.M116.738666

HOXC10 expression supports the development of chemotherapy resistance by fine tuning DNA repair in breast cancer cells
Sadik, H, Korangath, P, Nguyen, NK, Gyorffy, B, Kumar, R, Hedayati, M, Teo, WW, Park, S, Panday, H, Munoz, TG, Menyhart, O, Shah, N, Pandita, RK, Chang, JC, DeWeese, T, Chang, HY, Pandita, TK & Sukumar, S 2016, Cancer Research, vol 76, no. 15, pp. 4443-4456. DOI: 10.1158/0008-5472.CAN-16-0774

Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion
Mazumdar, A, Poage, GM, Shepherd, J, Tsimelzon, A, Hartman, ZC, Den Hollander, P, Hill, J, Zhang, Y, Chang, J, Hilsenbeck, SG, Fuqua, S, Kent Osborne, C, Mills, GB & Brown, PH 2016, Breast Cancer Research and Treatment, pp. 1-14. DOI: 10.1007/s10549-016-3892-y

Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: Results from a phase Ib/IIa study
Martin, M, Fumoleau, P, Dewar, JA, Albanell, J, Limentani, SA, Campone, M, Chang, JC, Patre, M, Strasak, A, de Haas, SL, Xu, J & Garcia-Saenz, JA 2016, Annals of Oncology, vol 27, no. 7, mdw157, pp. 1249-1256. DOI: 10.1093/annonc/mdw157

The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair
Liang, DH, Choi, DS, Ensor, JE, Kaipparettu, BA, Bass, BL & Chang, JC 2016, Cancer Letters, vol 376, no. 2, pp. 249-258. DOI: 10.1016/j.canlet.2016.04.002

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence
Balko, JM, Schwarz, LJ, Luo, N, Estrada, MV, Giltnane, JM, Dávila-González, D, Wang, K, Sánchez, V, Dean, PT, Combs, SE, Hicks, D, Pinto, JA, Landis, MD, Doimi, FD, Yelensky, R, Miller, VA, Stephens, PJ, Rimm, DL, Gómez, H, Chang, JC, Sanders, ME, Cook, RS & Arteaga, CL 2016, Science Translational Medicine, vol 8, no. 334, 334ra53. DOI: 10.1126/scitranslmed.aad3001

Phosphatase PTP4A3 promotes triple-negative breast cancer growth and predicts poor patient survival
Hollander, PD, Rawls, K, Tsimelzon, A, Shepherd, J, Mazumdar, A, Hill, J, Fuqua, SAW, Chang, JC, Osborne, CK, Hilsenbeck, SG, Mills, GB & Brown, PH 2016, Cancer Research, vol 76, no. 7, pp. 1942-1953. DOI: 10.1158/0008-5472.CAN-14-0673

A comparison between DASL and Affymetrix on probing the whole-transcriptome
Jeong, J, Audet, R, Chang, J, Wong, H, Willis, S, Young, B, Edgerton, S, Thor, A, Sledge, G, Duchnowska, R, Jassem, J, Adamowicz, K, Leyland-Jones, B & Shen, C 2016, Journal of the Korean Statistical Society, vol 45, no. 1, pp. 149-155. DOI: 10.1016/j.jkss.2015.09.001

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
Tanei, T, Choi, DS, Rodriguez, AA, Liang, DH, Dobrolecki, L, Ghosh, M, Landis, MD & Chang, JC 2016, Breast Cancer Research, vol 18, no. 1, 6. DOI: 10.1186/s13058-015-0662-4

Correlating mammographic and pathologic findings in clinical decision support using natural language processing and data mining methods
Patel, TA, Puppala, M, Ogunti, RO, Ensor, Jr. JE, He, T, Shewale, JB, Ankerst, DP, Kaklamani, VG, Rodriguez, AA, Wong, STC & Chang, JC 2016, Cancer. DOI: 10.1002/cncr.30245

Cancer stem cells: A nuanced perspective
Rich, JN, Matsui, WH & Chang, JC 2016, Medicine (United States), vol 95, no. 1, pp. S26-S28. DOI: 10.1097/MD.0000000000004559

c-Abl inhibits breast cancer tumorigenesis through reactivation of p53-mediated p21 expression
Morrison, CD, Allington, TM, Thompson, CL, Gilmore, HL, Chang, JC, Keri, RA & Schiemann, WP 2016, Oncotarget, vol 7, no. 45, pp. 72777-72794. DOI: 10.18632/oncotarget.11909

Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, JC 2016, Medicine (United States), vol 95, no. 1, pp. S20-S25. DOI: 10.1097/MD.0000000000004766

Breast cancer stem cells
Choi, DS, Rosato, RR & Chang, JC 2016, . in Molecular Pathology of Breast Cancer. Springer International Publishing, pp. 133-151. DOI: 10.1007/978-3-319-41761-5_10

Cell-free DNA as a molecular tool for monitoring disease progression and response to therapy in breast cancer patients
Liang, DH, Ensor, JE, Liu, ZB, Patel, A, Patel, TA, Chang, JC & Rodriguez, AA 2016, Breast Cancer Research and Treatment, vol 155, no. 1, pp. 139-149. DOI: 10.1007/s10549-015-3635-5